Furthermore, we developed new antisense oligonucleotides (ASO) targeting TUG1 coupled with a potent drug delivery system (DDS), which can be used intravenously to provide efficient and selective delivery to glioma cells at sufficient concentrations to acquire antitumour effects20. This evidence concerns the gene TUG1 and central nervous system cancer.